Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving the way for a sales rebound later this year.The stock rose as much as 6.9% in Copenhagen as investors looked past a trimmed financial forecast from the Danish drugmaker.

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on Wednesday, ending a four-year stretch of steady guidance increases since the launch of its Wegovy weight-loss drug,

The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, particularly in the U.S.